Does MDS treatment cause hair loss and when does it grow back

Hair Loss and MDS Treatment: What You Should Know

Hair loss is a common concern for patients undergoing cancer treatment, and it's important to understand what to expect with MDS therapies.

Which MDS Treatments Can Cause Hair Loss?

Hair loss risk varies significantly depending on the specific treatment:

Higher Risk of Hair Loss:

• Intensive chemotherapy (used in some MDS cases, particularly higher-risk disease) - these drugs are more likely to cause noticeable hair loss
• Stem cell/bone marrow transplantation - can cause hair loss due to the intensive conditioning regimens used

Lower Risk of Hair Loss:

• Hypomethylating agents (HMAs) like azacitidine and decitabine - these are commonly used for MDS and typically cause minimal to no hair loss
• Targeted therapies like ivosidenib and enasidenib (for IDH mutations) - generally do not cause significant hair loss
• Imetelstat and luspatercept (for anemia management) - not typically associated with hair loss
• Lenalidomide (for del(5q) MDS) - rarely causes hair loss
• Supportive care (transfusions, growth factors) - does not cause hair loss

According to the NCCN Guidelines for MDS, most lower-risk and intermediate-risk MDS patients are managed with HMAs or targeted therapies, which have a much lower hair loss risk compared to intensive chemotherapy.

When Does Hair Grow Back?

If hair loss does occur:

• Timeline: Hair typically begins to regrow 2-3 months after treatment ends
• Full recovery: Most people see substantial regrowth within 6-12 months
• Hair characteristics: New hair may initially feel different in texture or color but usually returns to normal

Important Questions to Ask Your Doctor

1. Which specific treatment(s) am I receiving? This determines your actual hair loss risk
2. Based on my MDS type and risk category, what is the likelihood I'll experience hair loss?
3. If I do lose hair, what supportive options are available? (wigs, scarves, scalp cooling devices)
4. Should I take any preventive measures before starting treatment?
5. How will we monitor my response to treatment, and might my treatment plan change?

Key Takeaway

Most MDS patients—particularly those with lower-risk disease managed with hypomethylating agents or targeted therapies per NCCN Guidelines—experience little to no hair loss. However, your individual risk depends on your specific diagnosis, disease risk category, and treatment plan. This is definitely worth discussing in detail with your oncology team, as they can give you personalized information based on your exact situation.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.